Pathways to biomedical tipping points: Vertical, horizontal or other

Mark J. Ahn, Anne S. York, Polly Rizova

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.

Original languageEnglish
Pages (from-to)224-238
Number of pages15
JournalJournal of Commercial Biotechnology
Volume16
Issue number3
DOIs
StatePublished - Jul 2010

Fingerprint

Intellectual Property
Biomedical Technology
Organizations
Technology
Equipment and Supplies
Intellectual property
Growth
Innovation
Pathway
Vertical integration
Critical mass
Diagnostics
Breakthrough innovation

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Management of Technology and Innovation
  • Economics and Econometrics

Cite this

Pathways to biomedical tipping points : Vertical, horizontal or other. / Ahn, Mark J.; York, Anne S.; Rizova, Polly.

In: Journal of Commercial Biotechnology, Vol. 16, No. 3, 07.2010, p. 224-238.

Research output: Contribution to journalReview article

Ahn, Mark J. ; York, Anne S. ; Rizova, Polly. / Pathways to biomedical tipping points : Vertical, horizontal or other. In: Journal of Commercial Biotechnology. 2010 ; Vol. 16, No. 3. pp. 224-238.
@article{822e221ff60f4525b38b5e6ae22ddb5b,
title = "Pathways to biomedical tipping points: Vertical, horizontal or other",
abstract = "Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.",
author = "Ahn, {Mark J.} and York, {Anne S.} and Polly Rizova",
year = "2010",
month = "7",
doi = "10.1057/jcb.2010.4",
language = "English",
volume = "16",
pages = "224--238",
journal = "Journal of Commercial Biotechnology",
issn = "1462-8732",
publisher = "ThinkBiotech",
number = "3",

}

TY - JOUR

T1 - Pathways to biomedical tipping points

T2 - Vertical, horizontal or other

AU - Ahn, Mark J.

AU - York, Anne S.

AU - Rizova, Polly

PY - 2010/7

Y1 - 2010/7

N2 - Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.

AB - Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significant scientific progress. The pathways to their commercial success, however, are poorly understood. In contrast to recent calls for a return to vertical integration, we suggest that relying on strong and unique horizontal relationships among biomedical organizations is more likely to shape technology convergence and increase success rates in achieving a tipping point or critical mass to address unmet medical needs, build new intellectual property and extend profitable growth from served markets.

UR - http://www.scopus.com/inward/record.url?scp=77954117339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954117339&partnerID=8YFLogxK

U2 - 10.1057/jcb.2010.4

DO - 10.1057/jcb.2010.4

M3 - Review article

AN - SCOPUS:77954117339

VL - 16

SP - 224

EP - 238

JO - Journal of Commercial Biotechnology

JF - Journal of Commercial Biotechnology

SN - 1462-8732

IS - 3

ER -